At initiation of parenteral prostacyclin therapy, 62% of patients had intermediate-high COMPERA 2.0 risk status, whereas at ...

The U.S. Food and Drug Administration has declined to approve Zealand Pharma's bowel disease drug and sought an additional ...

CEO Brian Niccol said in a note to employees: “Our success starts and ends with our green apron partners. That’s why making ...

1 Nutrition Nurses, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, UK We read with interest the recent Cochrane review1 about home parenteral nutrition ...

Read also: USFDA nod to Gland Pharma Vitamin K deficiency treatment drug Gland Pharma was established in 1978 in Hyderabad ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

The FDA has denied Zealand Pharma’s approval bid for glepaglutide—a possible challenger to Takeda’s Gattex—in short bowel ...

Purpose: The technical issues surrounding the use of albumin in parenteral nutrient (PN) solutions are reviewed. Summary: Five criteria have been suggested to determine which compounds are optimal ...

No. 51 / 2024 U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for ...

Copenhagen, Denmark Monday, December 23, 2024, 12:00 Hrs [IST] ...